COVID-19 Business Intelligence and Analysis for Clinical Laboratories, Pathology Groups and Hospital Administration
Reliable COVID-19 Business Intelligence and analysis for clinical laboratories, pathology groups and Laboratory Diagnostics.
An exclusive interview with Richard S. Cooper of the firm McDonald Hopkins addresses two categories of legal risks that have become evident for clinical laboratories with COVID-19 testing.
Repeat SARS-CoV-2 testing has been an issue that many clinical laboratories and pathology groups have encountered, making it a potential lab test utilization issue.
In mid-March, it was critical to provide regulatory flexibility for serology test developers. However, two major issues have surged through public and political discourse.
There’s good news coming for clinical laboratories as a tidal wave of orders for COVID-19 serology tests head their way while healthcare policymakers call upon tens of millions of Americans to be tested in the coming weeks and months for the COVID-19 antibodies. This will be the single largest medical
Crowdsourced data during COVID-19 pandemic has implications for clinical laboratories and pathology groups, including possibly predicting test volume.
What we know about the CDC’s SPHERES’ (SARS-CoV-2 Sequencing for Public Health Emergency Response, Epidemiology, and Surveillance) objectives.
An exclusive interview with Richard S. Cooper of the firm McDonald Hopkins addresses two categories of legal risks that have become evident for clinical laboratories with COVID-19 testing.
Repeat SARS-CoV-2 testing has been an issue that many clinical laboratories and pathology groups have encountered, making it a potential lab test utilization issue.
In mid-March, it was critical to provide regulatory flexibility for serology test developers. However, two major issues have surged through public and political discourse.
There’s good news coming for clinical laboratories as a tidal wave of orders for COVID-19 serology tests head their way while healthcare policymakers call upon tens of millions of Americans to be tested in the coming weeks and months for the COVID-19 antibodies. This will be the single largest medical
Crowdsourced data during COVID-19 pandemic has implications for clinical laboratories and pathology groups, including possibly predicting test volume.
What we know about the CDC’s SPHERES’ (SARS-CoV-2 Sequencing for Public Health Emergency Response, Epidemiology, and Surveillance) objectives.
